Gloriosa
Randomised multicentre, open-label, phase 3 of mirvetuximab soravtansine in combination with bevacizumab vs bevacizumab alone as maintenance therapy for patients with FRĪ±-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab.
Description: This trial is for patients with platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers. The trial compares bevacizumab alone vs mirvetuximab soravtansine + bevacizumab
Study Phase: Phase 3
Principal Investigator: Prof Karen Cadoo
Further information